Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Targeting transcription and translation of the antisense CCCCGG repeat expansion in C9ORF72 ALS/FTD

Award Number: F31NS141619
ORGANIZATION: NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: FELLOWSHIP/SCHOLARSHIP/STUDENT LOANS
PERIOD OF PERFORMANCE START DATE: 01/01/2025
PERIOD OF PERFORMANCE END DATE: 12/31/2026

Group Awards By:

View Award Description

Targeting transcription and translation of the antisense CCCCGG repeat expansion in C9ORF72 ALS/FTD - PROJECT SUMMARY Amyotrophic lateral sclerosis (ALS) and frontotemporal degeneration (FTD) are devastating neurodegenerative diseases with no cure to date. The most common genetic cause of ALS/FTD is a hexanucleotide GGGGCC (G4C2) repeat expansion mutation in the C9ORF72 gene. The repeat is transcribed in both directions, producing sense G4C2 and antisense CCCCGG (C4G2) transcripts that are translated into six dipeptide repeat (DPR) proteins. The GGGGCC mutation is thought to cause ALS via three non-mutually exclusive mechanisms: a loss- of-function mechanism due to reduced expression of C9ORF72 protein, and gain-of-function mechanisms due to toxic repeat-containing RNA and/or DPRs. Sense and antisense RNA and DPRs accumulate in the central nervous system of C9ORF72 ALS/FTD patients and have been shown to be toxic in multiple model systems. To date, most studies have focused on the transcription and translation of the sense GGGGCC transcript. Hence, we know very little about how the antisense CCCCGG RNA is transcribed and translated. Importantly, recent clinical trials only targeting sense GGGGCC transcripts failed, suggesting that antisense CCCCGG RNAs and their DPRs should be explored as therapeutic targets. In Aim 1 of this proposal, the yet-unknown transcription start site (TSS) of the antisense transcript will be located using 5’ Rapid Amplification of cDNA Ends (RACE). Upon locating putative TSSs, the site(s) will be functionally validated via CRISPR/Cas9 mutagenesis in C9ORF72 patient-derived induced pluripotent stem cells (iPSCs). Then, I will target the TSS via CRISPR interference (CRISPRi) - a catalytically inactive Cas9 enzyme will interfere with transcription of the antisense strand, and the effects of blocking antisense strand transcription will be assessed in vitro using iPSC-derived motor neurons. In Aim 2, antisense oligonucleotides (ASOs) will be used to selectively degrade antisense repeat RNA. First, the candidate ASOs will be assessed for their ability to decrease DPR and transcript expression and reduce cell death in vitro using iPSC-derived motor neurons. Next, candidate ASOs will be administered to mice expressing 35 copies of the antisense CCCCGG repeat to determine whether they can rescue ALS/FTD pathology and symptoms. Altogether, successful completion of this proposal will elucidate a new target (antisense CCCCGG repeat RNA) of therapeutic interest for ALS/FTD. Such knowledge may be relevant for multiple other neurodegenerative diseases which are caused by bidirectionally-transcribed repeat expansions, including Huntington’s disease, spinocerebellar ataxias, and Friedreich ataxia.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2026 ( Subtotal = $50,114 )
2026	2026	UNIVERSITY OF CHICAGO	5801 S ELLIS AVE	CHICAGO	IL	60637	COOK	USA	Extramural Research Programs in the Neurosciences and Neurological Disorders	000	2	12/16/2025	NON-COMPETING CONTINUATION	$49,538
2026	2026	UNIVERSITY OF CHICAGO	5801 S ELLIS AVE	CHICAGO	IL	60637	COOK	USA	Extramural Research Programs in the Neurosciences and Neurological Disorders	001	2	4/27/2026	NON-COMPETING CONTINUATION	$576
														Subtotal = $50,114

Issue Date FY: 2024 ( Subtotal = $48,974 )
2024	2024	UNIVERSITY OF CHICAGO	5801 S ELLIS AVE	CHICAGO	IL	60637	COOK	USA	Extramural Research Programs in the Neurosciences and Neurological Disorders	000	1	9/20/2024	NEW	$48,974
														Subtotal = $48,974

Grand Total All Awards = $99,088

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Targeting transcription and translation of the antisense CCCCGG repeat expansion in C9ORF72 ALS/FTD

Award Number: F31NS141619

ORGANIZATION: NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: FELLOWSHIP/SCHOLARSHIP/STUDENT LOANS

PERIOD OF PERFORMANCE START DATE: 01/01/2025

PERIOD OF PERFORMANCE END DATE: 12/31/2026

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer